Vanguard Group
TOVX icon

Vanguard Group’s Theriva Biologics TOVX Stock Holding History

Vanguard Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$53.7K Buy
255,727
+239,345
+1,461% +$70.8K ﹤0.01% 4237
2025
Q3 		$6.63K Buy
+16,382
New +$7.09K ﹤0.01% 4341
2024
Q3 		– Sell
-7,780
Closed -$46K – 4385
2024
Q2 		$46K Sell
7,780
-1,231
-14% -$10.8K ﹤0.01% 4297
2024
Q1 		$106K Sell
9,011
-5,652
-39% -$66.1K ﹤0.01% 4238
2023
Q4 		$158K Sell
14,663
-5,848
-29% -$72K ﹤0.01% 4252
2023
Q3 		$277K Sell
20,511
-504
-2% -$7.66K ﹤0.01% 4198
2023
Q2 		$525K Hold
21,015
– – ﹤0.01% 4109
2023
Q1 		$367K Hold
21,015
– – ﹤0.01% 4203
2022
Q4 		$239K Buy
21,015
+12
+0.1% +$218 ﹤0.01% 4275
2022
Q3 		$518K Sell
21,003
-183
-0.9% -$7.02K ﹤0.01% 4200
2022
Q2 		$1.13M Hold
21,186
– – ﹤0.01% 4044
2022
Q1 		$1.51M Buy
21,186
+192
+0.9% +$13.1K ﹤0.01% 4069
2021
Q4 		$1.43M Buy
20,994
+12,935
+161% +$1.22M ﹤0.01% 4159
2021
Q3 		$925K Hold
8,059
– – ﹤0.01% 4262
2021
Q2 		$1.21M Hold
8,059
– – ﹤0.01% 4115
2021
Q1 		$1.37M Buy
8,059
+7,913
+5,420% +$1.56M ﹤0.01% 3939
2020
Q4 		$14K Sell
146
-348
-70% -$30.5K ﹤0.01% 4201
2020
Q3 		$59K Buy
494
+421
+577% +$56.2K ﹤0.01% 4057
2020
Q2 		$9K Hold
73
– – ﹤0.01% 4072
2020
Q1 		$6K Hold
73
– – ﹤0.01% 4078
2019
Q4 		$9K Hold
73
– – ﹤0.01% 4117
2019
Q3 		$8K Hold
73
– – ﹤0.01% 4147
2019
Q2 		$10K Sell
73
-156
-68% -$22.4K ﹤0.01% 4163
2019
Q1 		$39K Buy
229
+65
+40% +$10.8K ﹤0.01% 4076
2018
Q4 		$23K Sell
164
-377
-70% -$89.5K ﹤0.01% 4114
2018
Q3 		$352K Buy
541
+7
+1% +$7.74K ﹤0.01% 3908
2018
Q2 		$1.12M Buy
534
+1
+0.2% +$2.3K ﹤0.01% 3657
2018
Q1 		$1.49M Buy
533
+8
+2% +$30.4K ﹤0.01% 3551
2017
Q4 		$2.33M Buy
525
+6
+1% +$37.5K ﹤0.01% 3377
2017
Q3 		$4.23M Buy
519
+21
+4% +$121K ﹤0.01% 3176
2017
Q2 		$2.46M Sell
498
-8
-2% -$39.8K ﹤0.01% 3325
2017
Q1 		$2.79M Buy
506
+300
+146% +$2.09M ﹤0.01% 3271
2016
Q4 		$1.38M Sell
206
-111
-35% -$1.14M ﹤0.01% 3481
2016
Q3 		$4.77M Buy
317
+1
+0.3% +$15K ﹤0.01% 3035
2016
Q2 		$4.97M Buy
316
+30
+10% +$565K ﹤0.01% 2987
2016
Q1 		$5.9M Buy
286
+8
+3% +$120K ﹤0.01% 2877
2015
Q4 		$5.56M Buy
278
+6
+2% +$127K ﹤0.01% 2942
2015
Q3 		$5.39M Buy
272
+48
+21% +$1.18M ﹤0.01% 2929
2015
Q2 		$5.58M Buy
224
+12
+6% +$241K ﹤0.01% 2959
2015
Q1 		$4.06M Buy
212
+54
+34% +$964K ﹤0.01% 3097
2014
Q4 		$2.02M Buy
158
+5
+3% +$67.2K ﹤0.01% 3286
2014
Q3 		$2.38M Buy
153
+18
+13% +$293K ﹤0.01% 3194
2014
Q2 		$2.04M Hold
135
– – ﹤0.01% 3258
2014
Q1 		$3.05M Buy
135
+47
+53% +$973K ﹤0.01% 3046
2013
Q4 		$1.17M Buy
88
+32
+57% +$404K ﹤0.01% 3370
2013
Q3 		$827K Buy
56
+19
+51% +$261K ﹤0.01% 3422
2013
Q2 		$564K Buy
+37
New +$506K ﹤0.01% 3444

Other funds holding TOVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group's TOVX Position: Q4 2025 in Review

Vanguard Group increased its Theriva Biologics (TOVX) stake by 1,461% in Q4 2025, buying an estimated $70.8K and bringing the position to 255,727 shares worth $53.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4237.

Vanguard Group first reported a position in TOVX in Q2 2013 and has held it in 47 quarters since. The position peaked at $5.9M in Q1 2016. 21 funds tracked by Wall St. Rank hold TOVX as of Q4 2025.

  • Vanguard Group held 255,727 shares of Theriva Biologics worth $53.7K as of Q4 2025.
  • Vanguard Group bought 239,345 Theriva Biologics shares in Q4 2025, an estimated $70.8K.
  • Theriva Biologics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4237 holding.
  • Vanguard Group first reported a position in Theriva Biologics in Q2 2013 and has held it in 47 quarters since.
  • Vanguard Group's Theriva Biologics position peaked at $5.9M in Q1 2016.
  • 21 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.